TherapeuticsMD, Inc. (TXMD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, TherapeuticsMD reported revenue of $3.0M, up 71.6% from $1.8M the year before. Net income was -$569,000 (a -18.8% net margin), or -$0.05 per diluted share. Operating margin was -145.3%. Operating activities generated $2.5M of cash. At fiscal year end, TherapeuticsMD held $37.7M in total assets against $10.8M in total liabilities.
Open the full interactive TherapeuticsMD financials → Quarterly statements, key ratios, valuation history and price charts.
TherapeuticsMD Key Stats
| Share Price | $1.96 |
|---|---|
| Market Cap | $22.8M |
| Revenue YoY Growth | +71.6% |
| 52-Week Range | $1.04 – $2.77 |
| Shares Outstanding | 11.6 million (basic, 2026 Q2) |
TherapeuticsMD Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $64.9M | $87.0M | $70.0M | $1.3M | $1.8M | $3.0M |
| Cost of Goods Sold | $16.0M | $18.8M | $1.4M | — | — | — |
| Gross Profit | $48.9M | $68.1M | $68.6M | $1.3M | — | — |
| Operating Income | -$155.5M | -$139.8M | $1.2M | -$8.5M | -$4.8M | -$4.4M |
| Pre-Tax Income | -$183.5M | -$172.4M | $1.1M | -$7.7M | -$2.3M | -$653,000 |
| Income Tax | — | — | -$110.9M | -$43,000 | -$31,000 | -$84,000 |
| Net Income | -$183.5M | -$172.4M | $112.0M | -$10.3M | -$2.2M | -$569,000 |
| Diluted EPS | -$33.50 | -$21.50 | $11.96 | -$0.98 | -$0.19 | -$0.05 |
TherapeuticsMD Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $784,000 | $893,000 | $724,000 | $869,000 |
| Net Income | $152,000 | -$619,000 | $95,000 | $155,000 |
| Diluted EPS | $0.01 | -$0.05 | $0.01 | $0.01 |
TherapeuticsMD Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | — | — | $5.1M | — |
| Current Assets | $128.4M | $119.5M | $55.4M | $11.8M | $12.3M | $14.4M |
| Total Assets | $181.6M | $169.5M | $90.5M | $43.3M | $38.8M | $37.7M |
| Current Liabilities | $59.2M | $252.9M | $46.8M | $6.9M | $5.2M | $4.8M |
| Total Long-Term Debt | $237.7M | $376.5M | — | — | — | — |
| Total Liabilities | $305.6M | $263.1M | $55.3M | $14.0M | $11.5M | $10.8M |
| Shareholders' Equity | -$124.0M | -$93.6M | $35.1M | $29.3M | $27.4M | $26.9M |
TherapeuticsMD Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$159.5M | -$142.7M | $9.4M | -$23.1M | $1.2M | $2.5M |
| Cash From Investing | -$1.6M | -$2.2M | — | — | — | — |
| Cash From Financing | $80.7M | $129.6M | — | — | — | — |
| Free Cash Flow | -$159.7M | -$142.7M | $9.3M | — | — | — |
Figures from TherapeuticsMD's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full TherapeuticsMD financials page for every line item.
TherapeuticsMD Company Profile
| Ticker | TXMD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boca Raton, Florida |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000025743 |
Frequently Asked Questions
What was TherapeuticsMD's revenue in fiscal 2025?
TherapeuticsMD (TXMD) reported revenue of $3.0M for fiscal 2025.
What is TherapeuticsMD's annual revenue history?
TherapeuticsMD's annual revenue by fiscal year: 2020: $64.9M; 2021: $87.0M; 2022: $70.0M; 2023: $1.3M; 2024: $1.8M; 2025: $3.0M.
What was TherapeuticsMD's net income in fiscal 2025?
TherapeuticsMD reported net income of -$569,000 for fiscal 2025.
What was TherapeuticsMD's earnings per share (EPS) in fiscal 2025?
TherapeuticsMD's diluted EPS was -$0.05 for fiscal 2025 (adjusted for any later stock splits).
What was TherapeuticsMD's revenue last quarter?
In its most recent reported quarter (2026 Q2), TherapeuticsMD reported revenue of $869,000.
How many shares of TherapeuticsMD are outstanding?
TherapeuticsMD reported a weighted average of 11.6 million basic shares outstanding in 2026 Q2.
What is TherapeuticsMD's market cap?
Based on its latest closing price, TherapeuticsMD (TXMD) has a market capitalization of about $22.8M.
When does TherapeuticsMD's fiscal year end?
TherapeuticsMD's fiscal year end, as registered with the SEC, is December 31.
Where is TherapeuticsMD headquartered?
TherapeuticsMD lists its business address in Boca Raton, Florida in its SEC filings.